Valuation Bio-Rad Laboratories, Inc.
Stocks
BIO
US0905722072
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
04:00:02 2026-11-06 pm EST
|
5-day change | 1st Jan Change | ||
| 381.57 USD | +3.41% |
|
+2.52% | +25.93% |
| Nov. 05 | RBC Raises Price Target on Bio-Rad Laboratories to $440 From $390, Keeps Outperform Rating | MT |
| Nov. 04 | Bio-Rad Laboratories Q3 Adjusted Earnings, Revenue Rise | MT |
Company Valuation: Bio-Rad Laboratories, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 22,439 | 12,460 | 9,399 | 9,182 | 8,212 | 10,251 | - | - |
| Change | - | -44.47% | -24.57% | -2.31% | -10.57% | 24.83% | - | - |
| Enterprise Value (EV) 1 | 22,439 | 11,868 | 8,992 | 8,730 | 7,874 | 9,502 | 9,286 | 9,144 |
| Change | - | -47.11% | -24.24% | -2.91% | -9.8% | 20.67% | -2.28% | -1.52% |
| P/E | 5.38x | - | -14.8x | -5.03x | 10.9x | 45.9x | 44.8x | 45.2x |
| PBR | - | 1.27x | 1.05x | 1.41x | 1.11x | - | - | - |
| PEG | - | - | - | -0x | -0x | -0.7x | 19.62x | -64.11x |
| Capitalization / Revenue | 7.68x | 4.45x | 3.52x | 3.58x | 3.18x | 3.99x | 3.93x | 3.88x |
| EV / Revenue | 7.68x | 4.24x | 3.37x | 3.4x | 3.05x | 3.7x | 3.56x | 3.46x |
| EV / EBITDA | 33.1x | 17.8x | 16.8x | 18.2x | 17.4x | 23.6x | 22.5x | 21x |
| EV / EBIT | 39.3x | 22.7x | 23.7x | 26.4x | 25.3x | 32.2x | 29.9x | 26.6x |
| EV / FCF | 41.9x | 127x | 24x | - | - | 32.3x | 27.6x | 25.8x |
| FCF Yield | 2.39% | 0.79% | 4.17% | - | - | 3.1% | 3.63% | 3.87% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 140.6 | - | -21.82 | -65.36 | 27.85 | 8.32 | 8.51 | 8.45 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,923 | 2,802 | 2,671 | 2,566 | 2,583 | 2,569 | 2,607 | 2,642 |
| EBITDA 1 | 677.5 | 667.9 | 535.9 | 479.5 | 453.2 | 401.9 | 412.2 | 436.1 |
| EBIT 1 | 571.2 | 524 | 378.9 | 331.3 | 311.6 | 295 | 310.7 | 344 |
| Net income 1 | 4,246 | -3,628 | -637.3 | -1,844 | 759.9 | 224.8 | 229.7 | 228.3 |
| Net Debt 1 | - | -592.5 | -407.6 | -452.1 | -337.7 | -749 | -965.4 | -1,107 |
| Reference price 2 | 755.57 | 420.49 | 322.89 | 328.51 | 302.99 | 381.57 | 381.57 | 381.57 |
| Nbr of stocks (in thousands) | 29,918 | 29,824 | 29,145 | 27,997 | 26,975 | 26,893 | - | - |
| Announcement Date | 2/10/22 | 2/16/23 | 2/15/24 | 2/13/25 | 2/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 45.86x | 3.7x | 23.64x | - | 10.25B | |
| 36.37x | 4.28x | 16.09x | 2.36% | 190B | |
| 22.04x | 3.74x | 13.39x | 2.79% | 125B | |
| 28.1x | 4.99x | 17.1x | 1.11% | 124B | |
| 34.01x | 3.25x | 13.13x | 2.1% | 99.31B | |
| 17.69x | 0.21x | 13.23x | 0.71% | 63.65B | |
| 43.19x | 3.82x | 12.99x | 1.97% | 57.71B | |
| 44.96x | 11.29x | 31.68x | -.--% | 53.26B | |
| 26.84x | 6.63x | 16.85x | 1.5% | 47.03B | |
| 44.32x | 3.5x | 13.01x | 0.49% | 36.15B | |
| Average | 34.34x | 4.54x | 17.11x | 1.45% | 80.64B | |
| Weighted average by Cap. | 32.09x | 4.38x | 16.05x | 1.75% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- BIO Stock
- Valuation Bio-Rad Laboratories, Inc.
Select your edition
All financial news and data tailored to specific country editions
